A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions

Cancer Research

Volumn 59, Issue 16, 1999, Pages 4095-4099

  Wiemels, Joseph L ^a   Pagnamenta, Alistair ^a   Taylor, G Malcolm ^b   Eden, Osborn B ^c   Alexander, Freda E ^d   Greaves, Mel F ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ST MARY S HOSPITAL   (United Kingdom)

^c Academic Unit of Paediatric Oncology   (United Kingdom)

^d UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE);

ADOLESCENT; ALLELE; ARTICLE; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; ENZYME POLYMORPHISM; GENE FUSION; GENE REARRANGEMENT; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL;

ACUTE DISEASE; ADULT; ALLELES; CHILD; CHILD, PRESCHOOL; DNA-BINDING PROTEINS; FEMALE; GENE REARRANGEMENT; HUMANS; INFANT; LEUKEMIA; LOSS OF HETEROZYGOSITY; MYELOID-LYMPHOID LEUKEMIA PROTEIN; NAD(P)H DEHYDROGENASE (QUINONE); PREGNANCY; PROTO-ONCOGENES; TRANSCRIPTION FACTORS;

EID: 0033566767     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (59)

1. Kersey, J. H. Fifty years of studies on the biology and therapy of childhood leukemia. Blood, 90: 4243-4251, 1997.
2. Greaves, M. A natural history for pediatric acute leukemia. Blood, 82: 1043-1051, 1993.
3. Pui, C-H., Kane, J. R., and Crist, W. M. Biology and treatment of infant leukemias. Leukemia (Baltimore), 9: 762-769, 1995.
4. Greaves, M. F. Workshop report. Infant leukemia biology, aetiology, and treatment. Leukemia (Baltimore), 10: 372-377, 1996.
5. Raimondi, S. C. Current status of cytogenetic research in childhood acute lymphoblastic leukemia. Blood, 81: 2237-2251, 1993.
6. Romana, S. P., Mauchauffe, M., Le Coniat, M., Chumakov, I., Le Paslier, D., Berger, R., and Bernard, O. A. The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion, Blood. 85: 3662-3670, 1995.
7. Golub, T. R., Barker, G. F., Bohlander, S. K., Hiebert, S. W., Ward, D. C., Bray Ward, P., Morgan, E., Raimondi, S. C., Rowley, J. D., and Gilliland, D. G. Fusion of the TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc. Natl. Acad. Sci. USA, 92: 4917-4921, 1995.
8. Greaves, M. F. Aetiology of acute leukaemia. Lancet, 349: 344-349, 1997.
9. Gale, K. B., Ford, A. M., Repp, R., Borkhardt, A., Keller, C., Eden, O. B., and Greaves, M. F. Backtracking leukemia to birth: identification of clonotypic gene fusion sequences in neonatal blood spots. Proc. Natl. Acad. Sci. USA, 94: 13950-13954, 1997.
10. Ford, A. M., Bennett, C. A., Price, C. M., Bruin, M. C., Van Wering, E. R., and Greaves, M. Fetal origins of the TEL-AML1 fusion gene in identical twins with leukemia. Proc. Natl. Acad. Sci. USA, 95: 4584-4588, 1998.
11. Taylor, G. M., and Birch, J. M. The hereditary basis of human leukemia. In: E. S. Henderson, T. A. Lister, and M. F. Greaves (eds.), Leukemia, Ed. 6, pp. 210-245. Philadelphia: W B Saunders, 1996.
12. Hietanen, E., Husgafvel-Pursiainen, K., and Vainio, H. Interaction between dose and susceptibility to environmental cancer: a short review. Environ. Health Perspect., 105: 749-754, 1997.
13. Chen, C. L., Liu, Q., Pui, C-H., Rivera, G. K., Sandlund, J. T., Ribeiro, R., Evans, W. E., and Relling, M. V. Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia. Blood, 89: 1701-1707, 1997.
14. Krajinovic, M., Labuda, D., Richer, C., Karimi, S., and Sinnett, D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood, 93: 1496-1501, 1999.
15. Taylor, G. M., Robinson, M. D., Binchy, A., Birch, J. M., Stevens, R. F., Jones, P. M., Carr, T., Dearden, S., and Gokhale, D. A. Preliminary evidence of an association between HLA-DPB1 *0201 and childhood common acute lymphoblastic leukaemia supports an infectious aetiology. Leukemia (Baltimore), 9: 440-443, 1995.
16. Pui, C-H., Relling, M. V., Rivera, G. K., Hancock, M. L., Raimondi, S. C., Heslop, H. E., Santana, V. M., Ribeiro, R. C., Sandlund, J. T., Mahmoud, H. H., Evans, W. E., Crist, W. M., and Krance, R. A. Epipodophyllotoxin-related acute myeloid leukemia: a study of 35 cases. Leukemia (Baltimore), 9: 1990-1996, 1995.
17. Rowley, J. D. The critical role of chromosome translocations in human leukemias. Annu. Rev. Genet., 32: 495-519, 1998.
18. Gu, Y., Alder, H., Nakamura, T., Schichman, S. A., Prasad, R., Canaani, O., Saito, H., Croce, C. M., and Canaani, E. Sequence analysis of the breakpoint cluster region in the ALL-1 gene involved in acute leukemia. Cancer Res., 54: 2326-2330, 1994.
19. Broeker, P. L., Harden, A., Rowley, J. D., and Zeleznik, L. N. The mixed lineage leukemia (MLL) protein involved in 11q23 translocations contains a domain that binds cruciform DNA and scaffold attachment region (SAR) DNA. Curr. Top. Microbiol. Immunol., 211: 259-268, 1996.
20. Cimino, G., Rapanotti, M. C., Biondi, A., Elia, L., Lo-Coco, F., Price, C., Rossi, V., Rivolta, A., Canaani, E., Croce, C. M., Mandelli, F., and Greaves, M. Infant acute leukemias show the same biased distribution of ALL1 gene breaks as topoisomerase II related secondary acute leukemias. Cancer Res., 57: 2879-2883, 1997.
21. Felix, C. A., Hosler, M. R., Slater, D. J., Parker, R. I., Masterson, M., Whitlock, J. A., Rebbeck, T. R., Nowell, P. C., and Lange, B. J. MLL genomic breakpoint distribution within the breakpoint cluster region in de novo leukemia in children. J. Pediatr. Hematol. Oncol., 20: 299-308, 1998.
22. Ford, A. M., Ridge, S. A., Cabrera, M. E., Mahmoud, H., Steel, C. M., Chan, L. C., and Greaves, M. In utero rearrangements in the trithorax-related oncogene in infant leukaemias. Nature (Lond.), 363: 358-360, 1993.
23. Ross, J. A., Potter, J. D., and Robison, L. L. Infant leukemia, topoisomerase II inhibitors, and the MLL gene. J. Natl. Cancer Inst., 86: 1678-1680, 1994.
24. Ross, J. A., Davies, S. M., Potter, J. D., and Robison, L. L. Epidemiology of childhood leukemia with a focus on infants. Epidemiol. Rev., 16: 243-272, 1994.
25. Ross, J. A., Potter, J. D., Reaman, G. H., Pendergrass, T. W., and Robison, L. L. Maternal exposure to potential inhibitors of DNA topoisomerase II and infant leukemia (United States): a report from the Children's Cancer Group. Cancer Causes Control, 7: 581-590, 1996.
26. Yamashita, Y., Kawada, S. Z., and Nakano, H. Induction of mammalian topoisomerase II dependent DNA cleavage by nonintercalative flavonoids, genistein and orobol. Biochem. Pharmacol., 39: 737-744, 1990.
27. Powis, G. Free radical formation by antitumor quinones. Free Radical Biol. Med., 6: 63-101, 1989.
28. Chen, H., and Eastmond, D. A. Topoisomerase inhibition by phenolic metabolites: a potential mechanism for benzene's clastogenic effects. Carcinogenesis (Lond.), 16: 2301-2307, 1995.
29. Frydman, B., Marton, L. J., Sun, J. S., Neder, K., Witiak, D. T., Liu, A. A., Wang, H. M., Mao, Y., Wu, H. Y., and Sanders, M. M. Induction of topoisomerase II-mediated DNA cleavage by β-lachone and related naphthoquinones. Cancer Res., 57: 620-627, 1997.
30. Leteurtre, F., Kohlhagen, G., and Pommier, Y. Streptonigrin induced topoisomerase II sites exhibit base preferences in the middle of the enzyme stagger. Biochem. Biophys. Res. Commun., 203: 1259-1267, 1994.
31. Ross, D. Metabolic basis of benzene toxicity. Eur. J. Haemotol., 57 (Suppl.): 111-118, 1996.
32. Traver, R. D., Horikoshi, T., Danenberg, K. D., Stadlbauer, T. H. W., Danenberg, P. V., Ross, D., and Gibson, N. W. NAD(P)H:Quinone oxidoreductase gene expression in human colon carcinoma cells: characterization of a mutation which modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res., 52: 797-802, 1992.
33. Pan, S. S., Forrest, G. L., Akman, S. A., and Hu, L. T. NAD(P)H:Quinone oxidoreductase expression and mitomycin C resistance developed by human colon cancer HCT 116 cells. Cancer Res., 55: 330-335, 1995.
34. Gaedigk, A., Tyndale, R. F., Jurima-Romet, M., Sellers, E. M., Grant, D. M., and Leeder, J. S. NAD(P)H:Quinone oxidoreductase: polymorphisms and allele frequencies in Caucasian, Chinese, and Canadian Native Indian and Inuit populations. Pharmacogenetics, 8: 305-313, 1998.
35. Traver, R. D., Siegel, D., Beall, H. D., Phillips, R. M., Gibson, N. W., Franklin, W. A., and Ross, D. Characterization of a polymorphism in NAD(P)H:quinone oxidoreductase (DT-diaphorase). Br. J. Cancer, 75: 69-75, 1997.
36. Siegel, D., McGuinness, S. M., Winski, S. L., and Ross, D. Genotype-phenotype relationships in studies of a polymorphism in NAD(P)H:quinone oxidoreductase 1. Pharmacogenetics, 9: 113-121, 1999.
37. Kelsey, K. T., Ross, D., Traver, R. D., Christiani, D. C., Zuo, Z-F.. Spitz, M., Wang, M., Xu, X., Lee, B-K., Schwanz, B. S., and Wiencke, J. K. Ethnic variation in the prevalence of a common NAD(P)H:quinone oxidoreductase polymorphism and its implications for anticancer chemotherapy. Br. J. Cancer, 76: 852-854, 1997.
38. Rosvold, E. A., McGlynn, K. A., Lustbader, E. D., and Buetow, K. H. Identification of an NAD(P)H:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics, 5: 199-206, 1995.
39. Schulz, W. A., Krummeck, A., Rosinger, I., Eickelmann, P., Neuhaus, C., Ebert, T., Schmitz-Drager, B. J., and Sies, H. Increased frequency of a null-allele for NAD(P)H: quinone oxidoreductase in patients with urological malignancies. Pharmacogenetics, 7: 235-239, 1997.
40. Thor, H., Smith, M. T., Hartzell, P., Bellomo, G., Jewell, N. A., and Orrenius, S. The metabolism of menadione (2-methyl-1,4-naphthoquinone) by isolated hepatocytes. A study on the implication of oxidative stress in intact cells. J. Biol. Chem., 257: 12419-12425, 1982.
41. Rothman, N., Smith, M. T., Hayes, R. B., Traver, R. D., Hoener, B., Campleman, S., Li, G. L., Dosemeci, M., Linet, M., Zhang, L., Xi, L., Wacholder, S., Lu, W., Meyer, K. B., Titenko Holland, N., Stewart, J. T., Yin, S., and Ross, D. Benzene poisoning, a risk factor for hematological malignancy, is associated with the NQO1 609C-→T mutation and rapid fractional excretion of chlorzoxazone. Cancer Res., 57: 2839-2842, 1997.
42. Joseph, P., and Jaiswal, A. K. NAD(P)H:Quinone oxidoreductase1 (DT diaphorase) specifically prevents the formation of benzo[a]pyrene quinone-DNA adducts generated by cytochrome P4501A1 and P450 reductase. Proc. Natl. Acad. Sci. USA, 91: 8413-8417, 1994.
43. Beyer, R. E., Segura-Aguilar, J., Di Bernardo, S., Cavazzoni, M., Fato, R., Fiorentini, D., Galli, M. C., Setti, M., Landi, L., and Lenaz, G. The role of DT-diaphorase in the maintenance of the reduced antioxidant form of coenzyme Q in membrane systems. Proc. Natl. Acad. Sci. USA, 93: 2528-2532, 1996.
44. Siegel, D., Bolton, E. M., Burr, J. A., Liebler, D. C., and Ross, D. The reduction of α-tocopherolquinone by human NAD(P)H:quinone oxidoreductase (hNQO1): the role of α-tocopherolquinone as a cellular antioxidant. Mol. Pharmacol., 52: 300-305, 1997.
45. Smith, M. T., Yager, J. W., Steinmetz, K. L., and Eastmond, D. A. Peroxidase-dependent metabolism of benzene's phenolic metabolites and its potential role in benzene toxicity and carcinogeneity. Environ. Health Perspect., 82: 23-29, 1989.
46. Deisinger, P. J., Hill, T. S., and English, J. C. Human exposure to naturally occurring hydroquinone. J. Toxicol. Environ. Health, 47: 31-46, 1996.
47. Gangousis, L. G., Goon, D., Zyglewska, T., K. K., W., and Ross, D. Cell-specific metabolism in mouse bone marrow stroma: studies of activation and detoxification of benzene metabolites. Mol. Pharmacol., 42: 1118-1125, 1992.
48. Thomas, D. J., Sadler, A., Subrahmanyam, V. V., Siegel, D., Reasor, M. J., Wierda, D., and Ross, D. Bone marrow stromal cell bioactivation and detoxification of the benzene metabolite hydroquinone: comparison of macrophages and fibroblastoid cells. Mol. Pharmacol., 37: 255-262, 1990.
49. Wiemels, J., Wiencke, J. K., Varkonyi, A., and Smith, M. T. Modulation of toxicity and macromolecular binding of benzene metabolites by NAD(P)Hequinone oxidoreductase in transfected HL-60 cells. Chem. Res. Toxicol., 12: 467-475, 1999.
50. Larson, R. A., Wang, Y., Banerjee, M., Wiemels, J., Hartford, C., LeBeau, M. M., and Smith, M. T. Presence of the inactivating polymorphism in the NAD(P)H:quinone oxidoreductase (NQO1) gene in patients with primary and therapy-related myeloid leukemia. Blood, 94: 803-807, 1999.
51. Parkin, D. M., Muir, C. S., Whekan, S. J., Gao, Y. T., Ferlay, J., and Powell, J. Cancer Incidence in Five Continents. IARC Scientific Pub., Vol. 120. Lyon, France: IARC, 1992.
52. Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N-K. V., Lovett, B. D., Nowell, P. C., Blair, I. A., and Rebbeck, T. R. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA, 95: 13176-13181, 1998.
53. Yang, H. Y., Lee, Q. P., Rettie, A. E., and Juchau, M. R. Functional cytochrome P4503A isoforms in human embryonic tissues: expression during organogenesis. Mol. Pharmacol., 46: 922-928, 1994.
54. Schuetz, J. D., Beach, D. L., and Guzelian, P. S. Selective expression of cytochrome P450 CYP3A mRNAs in embryonic and adult human liver. Pharmacogenetics, 4: 11-20, 1994.
55. Shu, X-O., Ross, J. A., Pendergrass, T. W., Reaman, G. H., Lampkin, B., and Robison, L. L. Parental alcohol consumption, cigarette smoking, and risk of infant leukemia: a Children's Cancer Group Study. J. Natl. Cancer Inst., 88: 24-31, 1996.
56. Metodiewa, D., Jaiswal, A. K., Cenas, N., Dickancaite, E., and Segura-Aguilar, J. Quercetin may act as a cytotoxic prooxidant after its metabolic activation to semiquinone and quinoidal product. Free. Radical Biol. Med., 26: 107-116, 1999.
57. Frantz, C. E., Chen, H., and Eastmond, D. A. Inhibition of human topoisomerase II in vitro by bioactive benzene metabolites. Environ. Health Perspect., 104: 1319-1323, 1996.
58. Repp, R., Borkhardt, A., Haupt, E., Kreuder, J., Brettreich, S., Hammermann, J., Nishida, K., Harbott, J., and Lampert, F. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis. Leukemia (Baltimore), 9: 210-215, 1995.
59. Pui, C-H., Frankel, L. S., Carroll, A. J., Raimondi, S. C., Shuster, J. J., Head, D. R., Crist, W. M., Land, V. J., Pullen, J., Steuber, C. P., Behm, F. G., and Borowitz, M. J. Clinical characteristics and treatment outcome of childhood acute lymphoblastic leukemia with the t(4;11)(q21;q23): a collaborative study of 40 cases. Blood, 77: 440-447, 1991.